Literature DB >> 2307668

Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.

I J Goldberg1, C A Scheraldi, L K Yacoub, U Saxena, C L Bisgaier.   

Abstract

Lipoprotein lipase (LPL)-mediated hydrolysis of triglycerides (TG) contained in chylomicrons requires the presence of a cofactor, apolipoprotein (apo) C-II. The physiological mechanism by which chylomicrons gain apoC-II necessary for LPL activation in whole plasma is not known. Using a gum arabic stabilized TG emulsion, activation of LPL by lipoprotein apoC-II was studied. Hydrolysis of TG by LPL was greater in the presence of serum than with addition of either high density lipoproteins (HDL) or very low density lipoproteins (VLDL). LPL activation by either VLDL or HDL increased with addition of the lipoprotein-free fraction of plasma. A similar increase in LPL activity by addition of the lipoprotein-free fraction together with HDL or VLDL was observed when another TG emulsion (Intralipid) or TG-rich lipoproteins from an apoC-II deficient subject were used as a substrate. Human apoA-IV, apoA-I, apoE, and cholesteryl ester transfer protein were assessed for their ability to increase LPL activity in the presence of VLDL. At and below physiological concentrations, only apoA-IV increased LPL activity. One hundred percent of LPL activity measured in the presence of serum was achieved using VLDL plus apoA-IV. In the absence of an apoC-II source, apoA-IV had no effect on LPL activity. Removal of greater than 80% of the apoA-IV from the nonlipoprotein-containing fraction of plasma by incubation with Intralipid markedly reduced its ability to activate LPL in the presence of VLDL or HDL. Gel filtration chromatography demonstrated that incubation of the nonlipoprotein-containing fraction of plasma with HDL and the TG emulsion caused increased transfer of apoC-II to the emulsion and association of apoA-IV with HDL. Our studies demonstrate that apoA-IV increases LPL activation in the presence of lipoproteins. We hypothesize that apoA-IV is required for efficient release of apoC-II from either HDL or VLDL, which then allows for LPL-mediated hydrolysis of TG in nascent chylomicrons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307668

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

2.  Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model.

Authors:  Yujie Cui; Mingwei Huang; Yingbo He; Shuyan Zhang; Yongzhang Luo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

3.  Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants.

Authors:  Pak Cheung Ng; Irene Ling Ang; Rossa Wai Kwun Chiu; Karen Li; Hugh Simon Lam; Raymond Pui On Wong; Kit Man Chui; Hon Ming Cheung; Eddy Wing Yin Ng; Tai Fai Fok; Joseph Jao Yiu Sung; Yuk Ming Dennis Lo; Terence Chuen Wai Poon
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

4.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.

Authors:  R D Cohen; L W Castellani; J H Qiao; B J Van Lenten; A J Lusis; K Reue
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

5.  Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women.

Authors:  Filiz Guclu-Geyik; Altan Onat; Neslihan Coban; Evrim Komurcu-Bayrak; Vedat Sansoy; Günay Can; Nihan Erginel-Unaltuna
Journal:  Mol Biol Rep       Date:  2012-10-25       Impact factor: 2.316

6.  Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.

Authors:  S F C Vaessen; G M Dallinga-Thie; C J D Ross; L J Splint; L W Castellani; P C N Rensen; M R Hayden; F G Schaap; J A Kuivenhoven
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

7.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Altered regulation of apolipoprotein A-IV gene expression in the liver of the genetically obese Zucker rat.

Authors:  W Strobl; B Knerer; R Gratzl; K Arbeiter; Y C Lin-Lee; W Patsch
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior.

Authors:  K Aalto-Setälä; C L Bisgaier; A Ho; K A Kieft; M G Traber; H J Kayden; R Ramakrishnan; A Walsh; A D Essenburg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.